ATAI Life Sciences BV (ATAI) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
ATAI Life Sciences BV stock (ATAI) is currently trading at $3.38. ATAI Life Sciences BV PS ratio (Price-to-Sales) is 310.01. Analyst consensus price target for ATAI is $13.45. WallStSmart rates ATAI as Sell.
- ATAI PE ratio analysis and historical PE chart
- ATAI PS ratio (Price-to-Sales) history and trend
- ATAI intrinsic value — DCF, Graham Number, EPV models
- ATAI stock price prediction 2025 2026 2027 2028 2029 2030
- ATAI fair value vs current price
- ATAI insider transactions and insider buying
- Is ATAI undervalued or overvalued?
- ATAI Life Sciences BV financial analysis — revenue, earnings, cash flow
- ATAI Piotroski F-Score and Altman Z-Score
- ATAI analyst price target and Smart Rating
ATAI Life Sciences BV
📊 No data available
Try selecting a different time range
Smart Analysis
ATAI Life Sciences BV (ATAI) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
ATAI Life Sciences BV (ATAI) Key Strengths (1)
Revenue surging 1773.00% year-over-year
Supporting Valuation Data
ATAI Life Sciences BV (ATAI) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Earnings declining -96.80%, profits shrinking
Very expensive at 310.0x annual revenue
Very expensive at 7.9x book value
Small-cap company with higher risk but more growth potential
Moderate institutional interest at 31.41%
Supporting Valuation Data
ATAI Life Sciences BV (ATAI) Detailed Analysis Report
Overall Assessment
This company scores 23/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 1 register as strengths (avg 10.0/10) while 7 fall into concern territory (avg 2.1/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth. Growth metrics are encouraging with Revenue Growth at 1773.00%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, EPS Growth. Some valuation metrics including Price/Sales (310.01), Price/Book (7.93) suggest expensive pricing. Growth concerns include EPS Growth at -96.80%, which may limit upside. Profitability pressure is visible in Return on Equity at -390.00%, Operating Margin at -3588.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -390.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 1773.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ATAI Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ATAI's Price-to-Sales ratio of 310.01x trades at a deep discount to its historical average of 1741.07x (30th percentile). The current valuation is 95% below its historical high of 6886.93x set in Oct 2025, and 554% above its historical low of 47.42x in Dec 2022. Over the past 12 months, the PS ratio has compressed from ~1733.5x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for ATAI Life Sciences BV (ATAI) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
ATAI Life Sciences BV is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 4M with 1773% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue growing at 1773% YoY, reaching 4M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 359% of revenue (15M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -29M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
Earnings fell 97% YoY while revenue grew 1773%. This gap usually reflects one-time items (tax benefits, write-offs) in the prior period, not an operational decline.
What to Watch Next
Growth sustainability: can ATAI Life Sciences BV maintain 1773%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 1.62, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact ATAI Life Sciences BV.
Bottom Line
ATAI Life Sciences BV is a high-conviction growth story with revenue accelerating at 1773% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About ATAI Life Sciences BV(ATAI)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
ATAI Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany.